Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)

NCT06592170 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Linperlisib combination with obinutuzumab

Sponsor

The First Hospital of Jilin University